EGFR and non-small cell lung carcinoma: The outcomes from multiple prospective phase III clinical trials have shown significantly better clinical efficacy in EGFR mutant advanced NSCLC patients initially treated with first- generation EGFR inhibitors (gefitinib or erlotinib) compared with upfront chemotherapy, with an objective response rate (ORR) of 71–83% and PFS of 9–13 months [8, 9].